Nick Haft

Delix is developing a class of novel non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles for the treatment of psychiatric and neurological indications.

Website

Freya is revolutionizing women's health through restoration of healthy vaginal microbiomes. Freya's first centers around improving the efficacy of in-vitro fertilization.

Website

Aperiam Bio uses computational methods to stabilize recombinant protein structures, solving a ubiquitous problem in industrial biotechnology. Using their computational approach, Aperiam Bio can produce enzymes with enhanced activity, shelf stability, and an expanded range of compatible reaction conditions, enabling a broad range of protein-based products.

Website

Replay is creating a novel, ambitious toolkit to deliver large DNA payloads efficiently to any cell type, addressing a rapidly growing cell and gene therapy market. Their platform includes a high-capacity HSV vector for gene delivery and a best-in-class hypoimmunogenic iPSC therapeutic platform.

Website

Stipple Bio intends to unlock cellular profiling and target discovery with epitope resolution. The company uses epitope-level resolution technology to enable single-cell profiling and target discovery, enabling users with therapies for a wide range of solid and hematologic malignancies.

Website

SyntheX has developed a yeast engineering approach that enables the discovery and design of peptide-based drugs with novel modes of action that block tough-to-drug protein-protein interactions (PPIs).

Website

VedaBio is revolutionizing molecular biology with its breakthrough platform for near-instant molecular detection of multiplexed analytes, delivering best-in-class accuracy without the need for target amplification. The CRISPR Cascade™ platform is poised to emerge as a new gold standard tool to empower decision-making across multiple industries.

Website

Finch is developing full spectrum and rationally selected microbiome-based drugs for the treatment of recurrent Clostridium Difficile infections, Autism Spectrum Disorder, Hepatitis B, Ulcerative Colitis, Crohn's disease, and several more.

Website

Bolstered by FDA’s breakthrough therapy designation, Compass is developing patent-protected psilocybin formulations for the treatment of intractable mood disorders.

Website